Calendar

AAR has strong company-reported growth and FY2027 guidance, but the checked sources did not verify positive current-quarter estimate revisions or a revenue-upside signal, and the stock fell sharply into the event with weak close locations; operating momentum alone does not overcome the tape and evidence gaps.

AutoZone has credible upcoming EPS and revenue estimates, positive recent operating momentum, and a modest three-month revenue-estimate increase, but EPS estimates drifted lower and the stock sold off sharply into the event while XLY weakened; the tape does not support an upside-surprise setup.

Thor has a credible consensus EPS and revenue source and some resilient motorized and European demand, but both EPS and revenue estimates were revised lower, management cut full-year EPS guidance, the stock fell sharply into earnings, and XLY was weak; this is a cyclical turnaround watch rather than a pre-earnings surprise setup.

KB Home has a recent built-to-order catalyst, a positive five-session bounce, a strong close location, and above-normal volume, but accessible estimates imply sharply lower year-over-year EPS and revenue, estimate revisions were not available, housing-sector tape was weak, and the latest EPS miss keeps this below the surprise threshold.

Ferguson has solid recent operating execution and credible consensus EPS and revenue estimates, but the accessible sources did not verify positive estimate revisions or a whisper edge, while the stock was in a pronounced decline into earnings; the evidence is insufficient for a surprise-oriented setup.

This is a low-coverage, pre-print monitoring view despite the queue's T+3 label. Company-source evidence is strong for the prior quarter, but no post-earnings results, market reaction, analyst revisions, target changes, or transcript was available. News tone is modestly constructive around the Royston strategy and scheduled report, while the deterministic prior has shifted negative and warrants caution.

Post-print price reaction cannot be isolated from the packet; the anchor price was $0.2205 on 2026-08-17. News tone is mixed: positive early PDS0301 data versus a negative strategic reset and liquidity profile. Social, options, short-interest, and employee data are unavailable; missing coverage is not positive evidence.

The T+3 earnings follow-up produces a mixed but cautious signal: Q2 GAAP earnings were positive, while headline Distributable Earnings was deeply negative because of realized losses. The stock was reported near $6.65 on the earnings date and the RankAlpha anchor was $6.83 on August 17, indicating only a modest recovery. Analyst revisions and detailed post-print market attribution are unavailable, so confidence in a bullish rerating remains limited [#SEC-8K-2026-08-11] [#PR-EARNINGS-2026-08-10].

News tone is modestly positive after the Q2 EPS beat and company-reported clinical milestones, but coverage is thin. Post-earnings analyst revisions, target changes, and a reliable T+3 price-reaction attribution are unavailable; social, options, short-interest, and employee data are also unavailable. Zero-valued fields represent missing data, not neutral signals.

Recent company and SEC materials are constructive on pipeline milestones and runway but mixed on reported financial performance. The T+3 follow-up has primary earnings confirmation, while analyst revisions and post-print price attribution remain unavailable; the deterministic prior has turned negative, supporting cautious monitoring rather than a high-conviction bullish view.

RNW was approximately flat at $6.82 intraday on August 18, providing no clear market confirmation of a post-earnings beat or miss. News coverage is event-focused, while analyst reaction and social coverage are unavailable; treat the setup as monitoring-oriented rather than directional.